Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease

The Lancet Gastroenterology and Hepatology

Volumn 3, Issue 1, 2018, Pages 66-72

  Rowe, Ian A ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; PIOGLITAZONE;

ALCOHOL CONSUMPTION; CLINICAL OUTCOME; COST UTILITY ANALYSIS; DEATH; DISEASE COURSE; EXERCISE; HEPATITIS C; HUMAN; INSULIN SENSITIVITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; METABOLOMICS; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; NOTE; OBESITY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STEATOSIS; SYSTEMATIC REVIEW (TOPIC); TRANSIENT ELASTOGRAPHY; WEIGHT REDUCTION; FEMALE; HEALTH SERVICE; MALE; MASS SCREENING; PREVALENCE;

FEMALE; HUMANS; MALE; MASS SCREENING; MEDICAL OVERUSE; NON-ALCOHOLIC FATTY LIVER DISEASE; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS;

EID: 85037609209     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30142-5     Document Type: Note

References (67)

1. Welch, HG, Schwartz, LM, Woloshin, S, Overdiagnosed: making people sick in the pursuit of health. 2011, Beacon Press, Boston, USA.
2. Carter, SM, Rogers, W, Heath, I, Degeling, C, Doust, J, Barratt, A, The challenge of overdiagnosis begins with its definition. BMJ, 350, 2015, h869.
3. Moynihan, R, Doust, J, Henry, D, Preventing overdiagnosis: how to stop harming the healthy. BMJ, 344, 2012, e3502.
4. Saini, V, Garcia-Armesto, S, Klemperer, D, et al. Drivers of poor medical care. Lancet 390 (2017), 178–190.
5. Brownlee, S, Chalkidou, K, Doust, J, et al. Evidence for overuse of medical services around the world. Lancet 390 (2017), 156–168.
6. Law, MR, Morris, JK, Wald, NJ, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
7. Ettehad, D, Emdin, CA, Kiran, A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
8. Younossi, ZM, Blissett, D, Blissett, R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64 (2016), 1577–1586.
9. European Association for the Study of the Liver European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
10. Connor, CL, Fatty infiltration of the liver and the development of cirrhosis in diabetes and chronic alcoholism. Am J Pathol 14 (1938), 347–64.9.
11. Ludwig, J, Viggiano, TR, McGill, DB, Oh, BJ, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980), 434–438.
12. Diehl, AM, Goodman, Z, Ishak, KG, Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95 (1988), 1056–1062.
13. Wanless, IR, Lentz, JS, Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990), 1106–1110.
14. Charlton, MR, Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there). Gastroenterology 140 (2011), 25–28.
15. Lazo, M, Hernaez, R, Bonekamp, S, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ, 343, 2011, d6891.
16. Kim, D, Kim, WR, Kim, HJ, Therneau, TM, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
17. Younossi, ZM, Koenig, AB, Abdelatif, D, Fazel, Y, Henry, L, Wymer, M, Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
18. Williams, CD, Stengel, J, Asike, MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
19. Harris, R, Harman, DJ, Card, TR, Aithal, GP, Guha, IN, Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol 2 (2017), 288–297.
20. Roulot, D, Costes, JL, Buyck, JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 60 (2011), 977–984.
21. Koehler, EM, Plompen, EP, Schouten, JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 63 (2016), 138–147.
22. Goldberg, D, Ditah, IC, Saeian, K, et al. Changes in the prevalence of hepatitis C virus infection, non-alcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 152 (2017), 1090–1099.
23. Setiawan, VW, Stram, DO, Porcel, J, Lu, SC, Le Marchand, L, Noureddin, M, Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology 64 (2016), 1969–1977.
24. Argo, CK, Northup, PG, Al-Osaimi, AM, Caldwell, SH, Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51 (2009), 371–379.
25. Adams, LA, Lymp, JF, St Sauver, J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
26. Angulo, P, Nonalcoholic fatty liver disease. N Engl J Med 346 (2002), 1221–1231.
27. Teli, MR, James, OF, Burt, AD, Bennett, MK, Day, CP, The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 (1995), 1714–1719.
28. Pais, R, Charlotte, F, Fedchuk, L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 59 (2013), 550–556.
29. McPherson, S, Hardy, T, Henderson, E, Burt, AD, Day, CP, Anstee, QM, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62 (2015), 1148–1155.
30. Singh, S, Allen, AM, Wang, Z, Prokop, LJ, Murad, MH, Loomba, R, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol, 13, 2015, 643 54.e1–9.
31. Ekstedt, M, Hagstrom, H, Nasr, P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
32. Angulo, P, Kleiner, DE, Dam-Larsen, S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 149, 2015, 389 97.e10.
33. Kleiner, DE, Brunt, EM, Van Natta, M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
34. Dulai, PS, Singh, S, Patel, J, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65 (2017), 1557–1565.
35. Lazo, M, Hernaez, R, Eberhardt, MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 178 (2013), 38–45.
36. Ruhl, CE, Everhart, JE, Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 124 (2003), 1821–1829.
37. Ioannou, GN, Weiss, NS, Boyko, EJ, Mozaffarian, D, Lee, SP, Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43 (2006), 1145–1151.
38. Armstrong, MJ, Adams, LA, Canbay, A, Syn, WK, Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
39. Pais, R, Giral, P, Khan, JF, et al. Fatty liver is an independent predictor of early carotid atherosclerosis. J Hepatol 65 (2016), 95–102.
40. Chimakurthi, CR, Rowe, IA, Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease. J Hepatol 65 (2016), 1265–1266.
41. Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149, 2015, 367 78.e5.
42. Ryan, MC, Itsiopoulos, C, Thodis, T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59 (2013), 138–143.
43. Johnson, NA, Sachinwalla, T, Walton, DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50 (2009), 1105–1112.
44. Moyer, VA, U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157 (2012), 373–378.
45. Colberg, SR, Sigal, RJ, Fernhall, B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 33 (2010), e147–e167.
46. National Institute for Health and Care Excellence. Non-alcoholic fatty liver disease (NAFLD): assessment and management. https://www.nice.org.uk/guidance/ng49?unlid=316728709201610221215552016, July, 2016 (accessed Nov 21, 2016).
47. Parker, R, Hodson, J, Rowe, IA, Systematic review: current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis. J Gastroenterol Hepatol, 2016 published online Oct 30. DOI:10.1111/jgh.13625.
48. Musso, G, Cassader, M, Paschetta, E, Gambino, R, Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges. Hepatology 65 (2016), 1058–1061.
49. Welch, HG, Black, WC, Overdiagnosis in cancer. J Natl Cancer Inst 102 (2010), 605–613.
50. NHS Digital. Hospital admitted care activity. http://content.digital.nhs.uk/searchcatalogue?q=title%3A%22Hospital+Episode+Statistics%2C+Admitted+patient+care+-+England%22&area=&size=10&sort=Relevance, 2016 (accessed Nov 21, 2016).
51. Office for National Statistics. The 21st century mortality files. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/the21stcenturymortalityfilesdeathsdataset, Nov 14, 2016 (accessed Nov 21, 2016).
52. Ekstedt, M, Franzen, LE, Mathiesen, UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
53. Gatineau, M, Hancock, C, Holman, N, et al. Adult obesity and type 2 diabetes. 2014, Public Health England, Oxford https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/338934/Adult_obesity_and_type_2_diabetes_.pdf (accessed Nov 21, 2016).
54. Sanyal, AJ, Abdelmalek, MF, Suzuki, A, Cummings, OW, Chojkier, M, No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology, 147, 2014, 377 84.e1.
55. Dormandy, J, Bhattacharya, M, van Troostenburg de Bruyn, AR, on behalf of the PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 32 (2009), 187–202.
56. Bjelakovic, G, Nikolova, D, Gluud, C, Antioxidant supplements to prevent mortality. JAMA 310 (2013), 1178–1179.
57. Bedson, J, McCarney, R, Croft, P, Labelling chronic illness in primary care: a good or a bad thing?. Br J Gen Pract 54 (2004), 932–938.
58. McDonald, SA, Hutchinson, SJ, Palmateer, NE, et al. Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. J Hepatol 58 (2013), 460–466.
59. Younossi, ZM, Henry, L, Economic and quality-of-life implications of non-alcoholic fatty liver disease. Pharmacoeconomics 33 (2015), 1245–1253.
60. Koretz, RL, Lin, KW, Ioannidis, JP, Lenzer, J, Is widespread screening for hepatitis C justified?. BMJ, 350, 2015, g7809.
61. Harman, DJ, Ryder, SD, James, MW, et al. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open, 5, 2015, e007516.
62. Crossan, C, Tsochatzis, EA, Longworth, L, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess 19 (2015), 1–409 v–vi.
63. Rose, G, Sick individuals and sick populations. Int J Epidemiol 14 (1985), 32–38.
64. Pavlov, CS, Casazza, G, Nikolova, D, Tsochatzis, E, Gluud, C, Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. Aliment Pharmacol Ther 43 (2016), 575–585.
65. Ferraioli, G, Tinelli, C, Dal Bello, B, et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 56 (2012), 2125–2133.
66. Cusi, K, Chang, Z, Harrison, S, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60 (2014), 167–174.
67. Barr, J, Caballeria, J, Martinez-Arranz, I, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 11 (2012), 2521–2532.